Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Carolina Digital Repository (University of North Carolina at Chapel Hill)

Topics

Computer Science

Quantum Mechanics

Physics

Medicine

Cancer Oncology

Show all topics

DOI

10.17615/d0f8-x010

License

CC-BY

Other Formats

PDF